Brus
★    

Spain,
2023-12-09 18:45
(520 d 13:12 ago)

Posting: # 23790
Views: 3,006
 

 Single-dose study in patients [Design Issues]

Dear All,

When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).

Thank you so much

Best regards,
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-12-10 10:43
(519 d 21:14 ago)

@ Brus
Posting: # 23791
Views: 2,398
 

 Single-dose study in patients

Hi Brus,

❝ When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).


A SD crossover is only possible for drugs in patients with a stable disease (e.g., theophylline in asthmatics). Otherwise, you have to opt for a parallel design.
  • Get PK data from the literature. Don’t use the average half life, be conservative (example).
  • Plan the study (first dose after the patients’ usual treatment, washout) with ≥ 5 × t½. If that’s longer than the common dosing interval → SD not possible.
  • Simulate concentrations (in Phoenix / Win­Non­lin’s ‘nonparametric superpostion’ module or even a spreadsheet) with your dose & regimen. If you would get pre-dose concentrations > 5% of Cmax in a substantial number of subjects → SD not possible.
  • If a SD study is not possible, you have to perform the study in steady state. Sorry.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
dshah
★★  

India,
2023-12-11 11:44
(518 d 20:13 ago)

@ Brus
Posting: # 23792
Views: 2,469
 

 Single-dose study in patients

Hi Brus!

❝ When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).


Generally the patient study is required to be performed for stabilized patient. How can treatment be discontinued in patient?

Regards,
Divyen
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
99 visitors (0 registered, 99 guests [including 52 identified bots]).
Forum time: 08:58 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5